within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AX29_Fostemsavir;

model Fostemsavir
  extends Pharmacolibrary.Drugs.ATC.J.J05AX29;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AX29</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Fostemsavir is an antiretroviral medication used for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection for whom an otherwise suppressive antiretroviral regimen is not available. It is a prodrug of temsavir, which acts as an attachment inhibitor binding to gp120 on HIV-1, preventing virus attachment and entry into host CD4+ cells. Fostemsavir is FDA- and EMA-approved.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics of temsavir (the active moiety of fostemsavir) in HIV-1-infected adults, following oral administration of fostemsavir 600 mg twice daily.</p><h4>References</h4><ol><li><p>Chahine, EB (2021). Fostemsavir: The first oral attachment inhibitor for treatment of HIV-1 infection. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 78(5) 376–388. DOI:<a href=\"https://doi.org/10.1093/ajhp/zxaa416\">10.1093/ajhp/zxaa416</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33547469/\">https://pubmed.ncbi.nlm.nih.gov/33547469</a></p></li><li><p>Magee, M, et al., &amp; Moore, K (2021). Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir. <i>Journal of clinical pharmacology</i> 61(7) 939–953. DOI:<a href=\"https://doi.org/10.1002/jcph.1810\">10.1002/jcph.1810</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33368327/\">https://pubmed.ncbi.nlm.nih.gov/33368327</a></p></li><li><p>Nwokolo, N, et al., &amp; Moore, K (2023). Fostemsavir and ethinyl estradiol drug interaction: Clinical recommendations for co-administration. <i>HIV medicine</i> 24(5) 580–587. DOI:<a href=\"https://doi.org/10.1111/hiv.13442\">10.1111/hiv.13442</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36372442/\">https://pubmed.ncbi.nlm.nih.gov/36372442</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Fostemsavir;
